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lthough substantial progress has been
achieved in both the diagnosis and treatment of schizo-
phrenia and the understanding of its neurobiological
substrates,a full understanding of its origins and path-
ogenic mechanisms remains elusive.Understanding the
development of schizophrenia is critical for developing
new treatment strategies, in part because early inter-
ventions—ie, secondary prevention—are associated
with better treatment outcomes.There is thus a grow-
ing emphasis on the accurate diagnosis of schizophre-
nia as soon as symptoms of psychosis are evident.Con-
ceptually,of course,the most effective treatment would
involve the prevention of psychosis altogether—ie,pri-
mary prevention.
Progress towards this goal, however, remains in its
infancy, in part because we are only just learning to
identify what the genetic liability to schizophrenia looks
like before the onset of psychosis.In this paper,we dis-
cuss recent progress in this area by focusing on “schizo-
taxia,”a clinically meaningful condition that may reflect
the liability for schizophrenia. We then consider an
important implication of identifying this condition: the
possibility of treatment strategies for the primary pre-
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Historically, the Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic criteria for schizo-
phrenia have emphasized several features, including symptoms of psychosis, a dissociation of symptoms
from their etiology, a reliance on clinical symptoms, and a categorical approach to classifying the disorder.
Although these emphases are quite useful, they have limitations. We review these here, and stress the
importance of incorporating recent data on the genetic / biological and neurodevelopmental origins of
schizophrenia into current conceptions of the disorder. We also review “schizotaxia,” which is a concept that
embodies this point of view, occurs before the onset of psychosis, and is hypothesized to represent the lia-
bility for schizophrenia. If our hypothesis on this point is correct, the identification of schizotaxic individuals
will eventually facilitate the development of prevention strategies by identifying a premorbid (but clinically
significant) condition for schizophrenia. Moreover, the identification of biological or neuropsychological
components of schizotaxia will provide more specific bases for developing novel treatment interventions.
Our initial attempts to develop protocols for the assessment and treatment of schizotaxia are encouraging,
and will be reviewed. 
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vention of schizophrenia. The development of the
notion of schizotaxia, however, begins with a review of
how schizophrenia has been classified over the last cen-
tury,especially in regard to the diagnostic emphasis on
symptoms of psychosis, the view of schizophrenia as a
discrete category,and the dissociation of clinical symp-
toms from their underlying genetic/biological etiolo-
gies. Limitations of these approaches are then consid-
ered, followed by ways in which genetic research has
helped to focus attention on phenotypic expressions of
schizophrenia genes (ie,schizotaxia) before the onset of
psychosis. Finally, clinical implications of schizotaxia
are considered.
The classification of schizophrenia: 
historical background
In 1895,Kraepelin distinguished dementia praecox from
manic-depressive psychoses.
1 Dementia praecox referred
to patients with global disruptions of perceptual and
cognitive processes (dementia), and early onsets (prae-
cox). These patients usually showed an onset in early
adulthood,and a progressively deteriorating course that
did not include a return to premorbid levels of function.
In contrast, manic-depressive features included rela-
tively intact thinking, a later onset, and an episodic
course in which episodes of psychopathology alternated
with periods of normal function.
Eugen Bleuler used Kraepelin’s systematic classification
of psychoses and a theoretical model of etiological
processes to reformulate dementia praecox as “schizo-
phrenia,” from the Greek words for “splitting of the
mind.”
2 His reasoning was that the defects in thinking in
schizophrenia were not identical to those occurring in
dementias associated with aging,for example,but instead
reflected deficits of “association.”Bleuler described four
basic symptoms:ambivalence,disturbance of association,
disturbance of affect, and a preference for fantasy over
reality. To Bleuler, these reflected schizophrenia’s fun-
damental defect:the disassociation or splitting of the nor-
mally integrated functions that coordinate thought,
affect, and behavior. It is important to note that, in con-
trast to subsequent Diagnostic and Statistical Manual of
Mental Disorders (DSM) criteria, Bleuler’s diagnosis of
schizophrenia did not depend on psychotic features such
as hallucinations and delusions.
Bleuler’s emphasis on theory as a means for determining
the diagnostic relevance of signs and symptoms con-
trasted sharply with Kraepelin’s reliance on empirical
observations. Bleuler’s approach was also notable for
other reasons.First,his reformulation of dementia prae-
cox as “the group of schizophrenias” foreshadowed the
modern view that schizophrenia is a heterogeneous
group of disorders with similar clinical presentations.
Second,Bleuler included defects in affect as a core fea-
ture of the disorder. Third, his view of schizophrenia
allowed for the possibility of remission or recovery.
Kraepelin’s and Bleuler’s observations provided the
foundation for contemporary systems of psychiatric clas-
sification, including the International Classification of
Disease and Death (ICD) and the American Psychiatric
Association’s DSM.These systems have thus benefited
from incisive clinical observations of, and conceptual-
izations about,schizophrenic illness.They also,however,
inherited the limitations of Kraepelin and Bleuler’s
efforts at classification and diagnosis.The first DSM def-
inition of schizophrenia was vague, unreliable, and
allowed for too much discretion on the part of clinicians.
As a result, apparent geographical differences arose in
the rates of schizophrenia. In the United States, schizo-
phrenia became the diagnosis of choice for psychotic
conditions that lacked a clear “organic” etiology, and
thus appeared to occur more frequently than it did in the
United Kingdom.
3 DSM-II continued the DSM-I tradi-
tion of unreliable diagnoses,although it did incorporate
the issue of differential diagnoses. Both of these early
systems viewed psychosis as a key feature of the disor-
der (we use the term psychosis to encompass hallucina-
tions,delusions,and gross disorganization of thought or
behavior).Interestingly,however,and despite its empha-
sis on psychosis,DSM-II did contain a nonpsychotic sub-
type of schizophrenia,called latent schizophrenia,which
included a heterogeneous group of patients who in
DSM-I were diagnosed with “incipient”or “borderline”
schizophrenia, among other conditions. As the term
“latent”implies,however,the category was intended to
encompass individuals with underlying or occult psy-
chotic conditions,instead of identifying individuals who
had schizophrenia in the absence of psychosis. Never-
theless,the category did represent an important attempt
to delineate the role of psychosis in schizophrenia.
DSM-III resulted largely from the efforts of the “neo-
Kraepelinian” movement of the 1960s and 1970s,
4 and
from the efforts of other investigators in psychiatry and
clinical psychology who argued for empirical,psychome-
tric validation of psychiatric syndromes (eg,reference 5).Liability for schizophrenia - Tsuang et al Dialogues in Clinical Neuroscience - Vol 1 . No.3 . 1999
DSM-III represented a marked shift from previous
DSMs,and contained a number of innovations,like field
tests of diagnostic reliability,specific inclusion and exclu-
sion criteria for diagnoses, multiaxial diagnosis, and a
focus on the description of syndromes and course of dis-
orders rather than inferences about their etiology. This
latter point made psychiatric diagnosis more explicitly
consistent with the diagnosis of other medical disorders
of uncertain etiology.
6,7
DSM-III’s use of clearly defined criteria narrowed the
construct of schizophrenia and in so doing improved its
diagnostic reliability. This improved the clinical homo-
geneity of the disorder and facilitated its delineation
from other serious mental illnesses. Still, DSM-III
retained the position that psychosis was fundamental to
the definition of schizophrenia,as Criterion “A”required
an hallucination or delusion at some point in the illness.
Similarly, Criterion A in DSM-III-R required “charac-
teristic psychotic symptoms.” In the latter revision, the
type of psychotic symptoms required for the diagnosis
was broadened to include gross behavioral disorganiza-
tion (eg,incoherence,catatonia,and grossly inappropri-
ate affect),although types of hallucinations or delusions,
by themselves,sufficed to meet the Criterion.
In DSM-IV, Criterion A could be met through a combi-
nation of delusions, hallucinations, and gross disorgani-
zation (of speech and/or behavior). Because 4 out of 5
symptoms are related to psychosis (negative symptoms
are the 5th symptom in the category), and Criterion A
requires at least 2 out of 5 symptoms,psychosis remains
necessary for the diagnosis of schizophrenia. Moreover,
delusions alone are enough to satisfy the Criterion if they
are bizarre, as are hallucinations, if they involve one or
more voices engaging in running commentary or ongoing
conversation.Thus,recent changes in DSM criteria have
expanded the nature of the psychotic symptoms required
for diagnosis, but have retained the emphasis on psy-
chosis in the construct of schizophrenia.
Although the evolution of the DSM is emphasized here
to trace the importance of psychosis in diagnostic clas-
sifications of schizophrenia, symptoms of psychosis—
especially delusions and hallucinations—are also core
features of ICD diagnostic criteria.The ICD-10 diagno-
sis of schizophrenia,for example,is heavily influenced by
the Schneiderian concept of “nuclear” schizophrenia,
which involves First-Rank Symptoms.As is well known,
these symptoms center on types of delusions and hallu-
cinations.
8
Limitations of the current view 
of schizophrenia
It is now generally agreed that stringent, narrow diag-
nostic criteria for schizophrenia and other mental dis-
orders were needed in the 1970s and 1980s to improve
the reliability of clinical diagnoses. They were also
needed to counteract the prevailing view that mental
illnesses were “myths” that harmed patients by stig-
matizing them with damaging diagnostic labels. Peri-
odic revisions of the major classificatory systems have
refined diagnoses further, increased their reliability,
facilitated the task of differential diagnosis, and pro-
vided the basis for empirical methods to determine
which symptoms most appropriately characterized spe-
cific disorders. Consequently, communications about,
and diagnoses of, mental disorders are far more stan-
dardized among mental health professionals and other
interested parties than they used to be, and the ratio-
nales for specific diagnostic criteria are much clearer.
The reliability of diagnosis provided by recent DSMs
has also benefited research to the extent that the clin-
ical characteristics of samples are more standardized
across studies and thus are more easily replicated.
Moreover, the use of stringent diagnostic criteria laid
the groundwork for studies to assess the validity of the
concept. In fact, the “modern” view of schizophrenia
(DSM-III and later) also has diagnostic validity.It can
be delineated from other disorders; for example, it
shows familial loading,and it predicts outcome (greater
levels of functional impairment predict larger numbers
of recurrent episodes).
Despite the many advances of DSM-III and its succes-
sors,however,we may still consider how the classifica-
tion of schizophrenia could be improved further.This is
not intended as a criticism of our progress thus far,but
instead reflects the need to modify our conceptual and
classificatory schemes as new information becomes
available. In this context, at least three limitations of
the current diagnostic criteria may be addressed,
including: its emphasis on psychosis, its definition of
schizophrenia as a discrete category,and its dissociation
of symptoms from their etiology. Each of these limita-
tions leads to the same issues: can the validity of the
diagnostic criteria for schizophrenia be increased while
its reliability is retained? More specifically, is the cur-
rent classification of schizophrenia the most accurate
reflection available of the biological condition that pro-
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duces it? Perhaps most importantly from a practical
point of view,would alternative conceptions of schizo-
phrenia promote the development of novel treatment
strategies? We address these issues, first, by revisiting
the issue of psychosis.
Psychosis and the definition of schizophrenia
As the previous discussion of DSM diagnostic criteria
emphasized, psychosis has long been the sine qua non
for schizophrenia.But is psychosis really a specific com-
ponent of schizophrenia, or is it more of a nonspecific
indicator of severe mental illness? A variety of evidence
supports the latter view. It is clear that psychosis is nei-
ther specific to schizophrenia, nor even to psychiatric
disorders.It occurs,for example,in neurological disease
(eg,Alzheimer disease,Huntington disease,schizophre-
nia-like psychosis of epilepsy, vascular dementia, and
traumatic brain injury) and can be caused by a range of
toxic substances or impaired metabolic states. Even
Schneiderian first-rank symptoms, which have played
such a prominent role in defining the nature of psychotic
symptoms in modern diagnostic systems, are not spe-
cific to schizophrenia.
9 Similarly, several recent factor-
analytic studies showed that measures of psychosis in
schizophrenia did not differentiate it from other forms
of psychopathology.
10,11
Bell et al,
12 for example, showed that duration of illness
and exclusion of affective symptoms correctly classified
97% of first-episode psychosis patients as having DSM-
III-R schizophrenia, and also correctly identified 97%
of such patients who did not have schizophrenia. The
inclusion of DSM-III-R’s psychosis criterion (Criterion
A) was not necessary to achieve these levels of sensitiv-
ity and specificity, nor did they improve the prediction.
Serretti et al
13 obtained a 4-factor solution for items on
the Operational Criteria Checklist for Psychotic Illness
among a large sample of DSM-III-R inpatients having
either schizophrenia or a mood disorder.Although they
found that two of their factors were more closely related
to affective disorders and two were more related to schiz-
ophrenia, the psychopathology of subjects with schizo-
phrenia overlapped that of bipolar patients on a “disor-
ganization” factor. Psychotic symptoms among other
diagnostic groups have also been noted,
14,15 although the
issue remains controversial (eg,reference 16).
Notably,several molecular genetic studies failed to find
linkage to schizophrenia on the basis of the DSM diag-
nosis,but instead showed stronger evidence for linkage
when the phenotype was broadened to include addi-
tional psychotic disorders (eg, Maziade et al
17 at chro-
mosome 6p and Wildenauer et al
18 at chromosome 18p).
Results from other genetic studies have also added to
converging evidence that different psychotic disorders
share common elements.
19 For example,at least one dis-
order in the schizophrenia spectrum—schizoaffective
disorder—might belong to an affective disorder spec-
trum as well.
19,20 Consistent with this view,schizoaffective
disorder occurs in families with either schizophrenia or
affective disorders. More generally, both schizophrenia
and affective disorders occur at elevated rates in families
with either disorder (eg, reference 21). Moreover, evi-
dence for genetic linkage for both types of psychotic
disorder has been obtained at similar chromosomal loci.
Ginns et al,
22 for example,obtained evidence for linkage
at 6p for bipolar disorder in Old Order Amish pedigrees,
near the same region that Maziade et al, and others,
have identified.
23 Similarly,the chromosome 10p region
was implicated for both schizophrenia and bipolar dis-
order in the National Institute of Mental Health
(NIMH) Genetics Initiative pedigrees,
24-26 and regions in
13q and 18p were also implicated recently in both of
these disorders.
19
One rationale for the similarities between psychotic
symptoms in different disorders may involve inherent
pathophysiological effects of psychosis. Several lines of
evidence support this possibility.One stems from obser-
vations that clinical outcomes of schizophrenia improve
when treatment is obtained early in the illness.
27 Another
involves the growing body of evidence that some
patients with schizophrenia show neurobiological abnor-
malities, such as enlarged ventricles, loss of tissue vol-
ume, degeneration of membrane phospholipids, and/or
delayed P300 waves in event-related potential para-
digms.
28 Recently,evidence consistent with the possibil-
ity of common neurobiological mechanisms across psy-
chotic conditions has emerged, involving, for example,
abnormal  -aminobutyric acid  (GABA)-ergic neuro-
transmission.
29
Thus,similarities in psychotic symptoms in different dis-
orders may be apparent at multiple genetic and (other)
biological levels, as well as phenomenologically. What
are the implications of such similarities? Crow proposed
a continuum of psychosis that crosses diagnostic bound-
aries,
30-32 and suggested that schizophrenia, schizoaffec-
tive disorder, and affective illness exist along one or
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more such continua. While he accepted the view that
prototypical entities corresponded to schizophrenia and
affective illness, he rejected the idea that they had dis-
tinct etiologies. Instead, he hypothesized that natural
variation along one or more dimensions produced the
prototypical disorders. He postulated that a common
genetic deficit, located in the pseudoautosomal region
of the sex chromosomes, was shared by psychotic dis-
orders, and hypothesized further that genes related to
psychosis were responsible for cerebral dominance and
the localization of language.
Support for the pseudoautosomal hypothesis is weak,
33-35
and a psychosis gene shared by all psychotic disorders
has yet to be discovered.Nevertheless,Crow’s view of
psychosis is intriguing. If, in fact, psychosis has an eti-
ology apart from other core symptoms of schizophre-
nia, then the DSM’s diagnostic focus on psychosis in
schizophrenia could be a mistake. In the hunt for the
causes of schizophrenia, psychosis could be a red
herring.
The foregoing discussion of common elements in psy-
choses is consistent with Crow’s notion of a contin-
uum of psychosis, in regard to its common phenome-
nology and etiology. It differs from Crow’s view,
however, in its implications for the construct of schiz-
ophrenia.Similarities between psychotic states do not
necessarily imply that the underlying disorders lie on
the same continuum.An alternative view is that since
psychotic states may impair functioning in a relatively
global manner,and may have adverse neuropatholog-
ical effects of their own, their net effect may be to
emphasize superficial similarities between such disor-
ders,while obscuring more subtle,but defining,differ-
ences between them.
In summary,we see two problems with the use of psy-
chosis as a sine qua non for schizophrenia. First,
mounting evidence suggests psychosis may be the
“fever” of severe mental illness. While it is a serious
problem,it is a nonspecific indicator.Second,psychosis
is an end-state condition that, in comparison with
other indicators,is a relatively distant consequence of
schizophrenia’s causes and pathophysiology. If these
views are correct, then the focus on psychosis may
actually hinder progress in searching for the causes of
schizophrenia. In the next two sections, we discuss
additional limitations of the diagnostic focus on psy-
chosis, and consider alternative conceptualizations of
schizophrenic illness.
DSM-IV schizophrenia is a discrete category
Like other disorders,DSM-IV defines schizophrenia as
a discrete category rather than a quantitative dimen-
sion, despite its qualification that “there is no assump-
tion that each category of mental disorder is a com-
pletely discrete entity with absolute boundaries dividing
it from other mental disorders or from no mental disor-
der”(p xxii,DSM-IV).
An implicit implication of this approach is that schizo-
phrenia differs qualitatively from states of health or
normalcy. This idea holds that schizophrenia begins
with the onset of its symptoms as listed in DSM-IV.
Before that time, the disorder cannot be recognized
validly; if the criteria for other disorders are also not
met, individuals cannot receive any psychiatric diag-
noses.To a significant degree, the “cut point” for mak-
ing the decision is whether psychotic symptoms are
present or not.
In general,a reliance on discrete categories raises poten-
tial problems for cases that share symptoms of multiple
disorders, because they may lead to artificial boundary
categories and elevated rates of comorbidity.
36 Certainly,
dimensional models of psychopathology have concep-
tual and pragmatic limitations as well.
37 For example,
although a variety of studies have identified underlying
dimensions of the diagnostic criteria for schizophrenia,
(eg,positive,negative,and disorganized symptoms),both
the number and the content of these dimensions remain
unclear.
38 These concerns are significant,but the question
remains as to whether a dimensional model describes
the biological nature of schizophrenia more accurately
than a categorical one? Is it more valid?
Certainly, a dimensional view of schizophrenia is more
consistent (than a categorical one) with polygenic mod-
els of inheritance, which is the model that provides the
best account of the familial transmission of schizophre-
nia.
23,39 Polygenic models assume that multiple genes
combine with one another and with environmental fac-
tors to cause schizophrenia.Because multiple genes and
environmental risk factors are involved, it is possible
for people to have low, moderate, or high “doses” of
risk factors that predispose to schizophrenia. People
with very high doses are at high risk for schizophrenia,
those with moderate doses may have related conditions
such as schizotypal personality disorder,negative symp-
toms, neuropsychological impairment, or other neuro-
biological manifestations of the predisposition to schiz-
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ophrenia.
40 It is clear that, in this view, a dimensional
model describes the range of schizophrenic illness bet-
ter than does a categorical one.
In fact, a partial foundation for a dimensional view of
the biological/clinical manifestations of the vulnerabil-
ity to schizophrenia already exists in the body of
research about “schizotaxia,” a term originally intro-
duced by Meehl
41 to describe the unexpressed genetic
predisposition to schizophrenia. Meehl suggested that
individuals with schizotaxia would develop either
schizotypy or schizophrenia, depending on the protec-
tion or liability afforded by environmental circum-
stances, although he later proposed that schizotaxia
need not progress into either of these more overt con-
ditions.
42 Given current data showing that,in addition to
genes, environmental events (eg, obstetric complica-
tions, viruses) augment susceptibility to schizophrenia,
Faraone et al
43 proposed that we use the term schizo-
taxia to indicate the premorbid, neurobiological sub-
strate of schizophrenia.
Now, almost 40 years after the idea of schizotaxia was
first advanced,a preponderance of evidence shows it to
be a clinically meaningful condition. In fact, studies of
nonschizotypal,nonpsychotic relatives of schizophrenic
patients show that schizotaxia is not merely a theoretical
construct,but has distinct psychiatric and neurobiologi-
cal features. These include negative symptoms, neu-
ropsychological impairment,impaired eye-tracking,and
structural brain abnormalities.
43
Schizotaxia is a broader construct than schizophrenia.
Our empirical studies suggest that the basic symptoms of
schizotaxia occurs in 20% to 50% of first-degree rela-
tives of schizophrenic patients.
40,44 In comparison, only
about 10% of relatives will become psychotic, and less
than 10% will develop schizotypal personality disor-
der.
45,46 These figures suggest that schizotaxia does not
lead inevitably to schizotypal personality or schizophre-
nia,but in most cases is a long-term condition.This leads
to the question of what type of etiological model
accounts best for a long-term biological vulnerability
(schizotaxia) that, under some circumstances, leads to
more serious conditions (schizophrenia).
Diagnostic criteria for schizophrenia ignore its etiology
and pathophysiology 
DSM-III (and later versions) explicitly dissociated diag-
nostic criteria from speculation about etiology to avoid
incorporating theories of etiology that were not sub-
jected to empirical tests.At this point, however, DSM-
III’s rejection of theoretical speculation about etiology
should not lead us to reject empirical facts about etiol-
ogy as being relevant to diagnosis or conceptualization.
Moreover,such a view risks a continuing disconnection
of treatment from etiology. Since the introduction of
antipsychotic medications, pharmacological treatments
have focused on alleviating the most acute,florid symp-
toms of schizophrenia, ie, those related to psychosis.
Although several newer antipsychotic medications also
alleviate selected negative symptoms and cognitive
deficits,treatment remains symptomatic.It is not aimed
at correcting specific causes of the disorder, nor is it
aimed at preventing its onset.
We recognize how counterintuitive it is to think of psy-
chosis as a somewhat nonspecific end state of schizo-
phrenia. But consider the evidence suggesting that
schizophrenia’s pathophysiology is put into place long
before the first psychotic episode. Many researchers
have sketched neurodevelopmental models of schizo-
phrenia based on adverse genetic and environmental
interactions occurring as early as the second trimester
of life (see, eg, refs 47-55). These events create a neu-
rodevelopmental syndrome, which, as studies of rela-
tives of schizophrenic patients have shown, is charac-
terized by neuropsychological,psychophysiological,and
neuroimaging abnormalities.
43 Evidence for neurode-
velopmental syndromes in schizophrenia is extensive
at this point, and emphasizes clinical, biological, and
neuropsychological abnormalities, both in individuals
who later develop schizophrenia, and in their nonpsy-
chotic biological relatives. For reasons that are still
unknown,this syndrome sometimes leads to psychosis,
and sometimes does not. Notably, these indicators of
the syndrome are more proximal to schizophrenia’s ini-
tial causes than is psychosis.
Clinical implications
Schizophrenia as a premorbid condition
Taken together,the evidence described above supports
the idea that schizophrenic disease begins before the
onset of psychosis, and expresses itself biologically in
characteristic ways.One way to integrate these findings
is to conceptualize its manifestations (eg, biological
abnormalities, biological relatedness to a family mem-
Basic researchber with schizophrenia, selected neuropsychological
deficits, and history of obstetric complications) as risk
factors that vary along dimensions of severity,for schizo-
phrenia.Schizotaxia describes this premorbid,yet clin-
ically significant, neurodevelopmental condition. Psy-
chosis, in contrast, represents a relatively less specific
consequence of schizophrenic disease than does schizo-
taxia.If our view is correct,then the clinical significance
of schizotaxia is related to both its (putative) status as a
discrete condition, and its status as a risk factor for
schizophrenia.
The emphasis on prepsychotic aspects of schizophrenic
illness, ie, schizotaxia, has potentially significant implica-
tions for the treatment of schizophrenia.For one,the iden-
tification of a premorbid condition, especially one that is
itself significant clinically,will facilitate the development of
early intervention strategies. Cameron (cited in ref 56)
first described, in 1938, the need to treat schizophrenia
early to prevent subsequent deterioration.As noted ear-
lier,evidence has since accumulated to support the view
that the longer treatment is delayed,the poorer the sub-
sequent prognosis.
27,57,58
Other benefits of early treatment are also likely,such as
the delay or prevention of the social,interpersonal,cog-
nitive,and affective disruptions that accompany and fol-
low an initial psychotic episode. One potential conse-
quence of secondary prevention is simply the delay of
onset. This may be especially valuable for early-onset
cases because these patients would then have more time
to mature before having to cope with a serious and
chronic illness. Moreover, untreated schizophrenia may
become more resistant to treatment,in part because psy-
chosis itself may create or lead to widespread neurobio-
logical abnormalities
28 that make treatment more com-
plicated and difficult.
The case for preventive treatment 
Research and theory about the early treatment of psy-
chosis naturally leads to the question: can psychosis be
avoided? That is, can schizophrenic illness be treated
before psychosis is added to it? Most researchers have
approached the issue of primary prevention by focus-
ing on prodromal symptoms as indicators of an impend-
ing psychotic disorder, but such symptoms are often
nonspecific. McGorry et al
59 showed, for example, that
DSM-III-R prodromal symptoms for schizophrenia
occurred in 15% to 50% of high-school students. This
raises obvious questions about the validity—and wis-
dom—of intervening on the basis of such symptoms.Are
prodromal indicators like social withdrawal or subtle
changes in thinking or affect valid enough indicators of
early schizophrenia to warrant intervention,which may
involve powerful antipsychotic medications and their
associated side effects? Is the cost/benefit analysis favor-
able enough to risk the potential anxiety and stigmati-
zation (for both “patients” and their families) that will
likely attend the classification of an individual as at-risk
for schizophrenia, probably in the near future? Unfor-
tunately, these questions cannot yet be answered in the
affirmative. In part because prodromal symptoms that
are specific to schizophrenia (or to other psychotic ill-
ness) are still unknown,
60 the application of primary pre-
vention programs appears premature in the absence of
clear clinical symptoms.
Among the steps that will make prevention efforts more
feasible for nonpsychotic individuals are,first,to identify
the population at risk,and second,to develop a rationale
for treatment.We propose that the study of schizotaxia
will help to achieve this goal.Given this hypothesis,what
are the next steps that must be taken to design a strategy
aimed at preventing schizophrenia? Clearly,the validity
of schizotaxia as a predictor of subsequent schizophrenia
must be firmly established.
As Robins and Guze
5 pointed out, it is crucial to estab-
lish both the concurrent and predictive validity of puta-
tive syndromes. Does the classification of schizotaxia
predict neuropsychological, neuroimaging, or psy-
chophysiologic findings that are consistent with what is
known about the neurobiology of schizophrenia? As we
have reviewed elsewhere, a growing body of literature
suggests that the answer is “yes.”
43Abnormalities found
among relatives of schizophrenic patients include eye-
tracking dysfunction,
61 allusive thinking,
62 neurologic
signs,
63 characteristic auditory evoked potentials,
64 neu-
roimaging-assessed brain abnormalities,
65 and neu-
ropsychological impairment.
66
More importantly, does schizotaxia predict the subse-
quent emergence of psychotic symptoms or other forms
of psychopathology? Studies of children at risk for schizo-
phrenia show that features of schizotaxia do predict sub-
sequent schizophrenia and related disorders (refs 67-70
and Erlenmeyer-Kimling L,1997,personal communica-
tion).Nevertheless,more work is needed to create meas-
ures of schizotaxia that will accurately classify children
who do and do not go on to develop schizophrenia.
159
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Although schizotaxic features cannot yet be used to
select preschizophrenic children for primary prevention
protocols,our current knowledge about schizotaxia sug-
gests a method for evaluating medications that may
someday be useful for the prevention of schizophrenia.
This method, which we call the “schizotaxia treatment
protocol” is straightforward: select a sample of schizo-
taxic first-degree relatives of schizophrenic patients
and,using standard randomized clinical trial methodol-
ogy, determine if a putative preventative treatment
modifies the features of schizotaxia in an acute trial.
Presumably, any medicine that mitigates the features of
schizotaxia will be a reasonable candidate for a primary
prevention trial when such trials are possible.
The use of the schizotaxia treatment protocol assumes
that the syndrome of schizotaxia observed among first-
degree relatives of schizophrenic patients shares etio-
logic and pathophysiologic pathways with preschizo-
phrenic subjects. If this assumption is true, then any
medication that targets these pathways to mitigate
schizotaxic features may also work to reduce the likeli-
hood of the onset of psychosis. This assumption is rea-
sonable because: (i) first-degree relatives of schizo-
phrenic patients are at high risk for carrying schizo-
phrenia susceptibility genes,
39 and (ii) the features of
schizotaxia observed among these relatives are similar
to those seen in children who eventually become schiz-
ophrenic.
43
A major advantage of the schizotaxia treatment proto-
col is that it can avoid some of the ethical issues raised
by primary prevention studies of schizophrenia.
Prevention studies will label children and adolescents
as potential future schizophrenics.As noted above,this
opens up the possibility of stigmatization and psycho-
logical harm to the subject and their families. It is also
possible that medications chosen for prevention trials
may pose greater risks to children and adolescents
than adults. That would preclude their use in the
absence of a solid rationale for efficacy. But, because
schizotaxia can be defined in the adult relatives of
schizophrenic patients, using an acute schizotaxia trial
for putative preventative medicines will not require
studies of children or adolescents.
If successful treatments are developed and tested, and
the syndrome of schizotaxia is validated, then treat-
ments at earlier ages may be considered. For example,
if an acute schizotaxia treatment trial in adults is suc-
cessful, one might consider an acute trial for adoles-
cents. If an adolescent trial were to be successful, then
we might consider a trial to prevent psychosis (assum-
ing that the target, preschizophrenic population could
be accurately defined).
One of the difficulties with implementing the schizotax-
ia treatment protocol is the lack of a consensual defini-
tion of schizotaxia.Although we can make many meas-
urements of schizotaxic features (eg, neuropsychologi-
cal symptoms, negative symptoms, social functioning),
the field has yet to agree on how these measures should
be combined to create a schizotaxic category.
Tsuang et al
71 recently described a working definition
of schizotaxia based on a set of specific criteria for the
purpose of developing a treatment protocol. In this ini-
tial approach, we diagnosed schizotaxia in people who
met the following criteria:
•They had at least one relative with schizophrenia;
•They had estimated IQs of 70 or higher;
•They had none of the following: lifetime history of
psychotic disorders; substance abuse diagnosis within
6 months of diagnosis; head injury with documented
loss of consciousness exceeding 5 minutes (or subse-
quent cognitive deficits);history of neurologic disease
or damage; medical condition with significant cogni-
tive sequelae; or a history of electroconvulsive treat-
ment;
•They had at least moderate levels of negative symp-
toms,defined as 6 items rated 3 or higher on the Scale
for the Assessment of Negative Symptoms (SANS
72);
•They had moderate or greater deficits (defined as
approximately two or more standard deviations below
appropriate norms) in at least one of three cognitive
domains:vigilance/working memory,long-term verbal
memory,and executive functions;
•They were at least one standard deviation below nor-
mal in a second cognitive domain (see ref 71) for lists
of specific tests and measures on tests used to meet the
neuropsychological criteria).
Our decision to require moderate deficits in different
domains ensured that our initial treatment attempts
would include only adults with demonstrable clinical
and neuropsychological difficulties.This was important
to demonstrate both the clinically meaningful nature of
schizotaxia, and also to make the risk/benefit assess-
ment of treatment more favorable.
Our first application of the schizotaxia treatment pro-
160
Basic researchtocol
71 used risperidone, a novel antipsychotic medica-
tion. As we noted above, trials of these medications
would appear reasonable on the basis of our assump-
tion that individuals with schizotaxia share etiological
and psychopathological elements with schizophrenia.
Trials with the older, typical antipsychotics, however,
were limited by reluctance to use these medications in
nonpsychotic populations, mainly because of their side
effects and subsequently high rates of noncompliance,
73
but also because of their essential inability to alleviate
negative symptoms
74 or neuropsychological deficits.
75
Another reason we chose risperidone was that, com-
pared with other novel antipsychotic medications, it
had (at the inception of the study) been shown to
reduce positive and some negative symptoms in schizo-
phrenia.
74,76,77 It was clearly safer than typical neurolep-
tics, in that it produced fewer extrapyramidal side
effects (at least at lower doses, eg, refs 74, 77). Notably,
it also improved cognitive functions in schizophrenia,
especially in attention or working memory,
76,78,79 but
possibly in verbal long-term memory
79 and executive
functions
76 as well. This latter feature was especially
important given that neuropsychological impairment is
a hallmark of schizotaxia.
Based on these issues, we began an open trial of
risperidone in people who met our criteria for schizo-
taxia.
71 After all entrance criteria were met, subjects
received low doses (starting at 0.25 mg and reaching
maximum doses of 2.0 mg) of risperidone for 6 weeks.
During that period, they were evaluated weekly for
side effects and for clinical and neuropsychological
effects of treatment. After 6 weeks, most clinical and
neuropsychological tests were repeated. We reported
on the effects of treatment in our first 4 cases
71 and
have since completed a fifth case.All subjects thus far
showed marked improvements in a demanding test of
auditory attention, and all subjects showed reduced
negative symptoms after 6 weeks. In 3 cases, reduc-
tions in negative symptoms were marked; in 2 they
were modest. Side effects, when they occurred, were
mild to moderate in severity.No one requested the dis-
continuation of treatment, but in some cases the doses
were lowered to reduce discomfort.
Future directions
Our initial application of the schizotaxia treatment pro-
tocol is encouraging, as all 5 cases showed reductions
in negative symptoms and neuropsychological deficits.
We stress the preliminary nature of these findings,how-
ever, and do not yet recommend the use of risperidone
or other medications to treat schizotaxia. Larger, con-
trolled studies are needed to determine if the treatment
implications of these pilot findings are correct.
Despite this caveat, however, our findings suggest the
feasibility of developing treatment strategies for adult
schizotaxia. It is clear that we are only starting this
process.Perhaps the most important tasks for the near
future, in addition to the need for more methodologi-
cally rigorous replications, is the validation of schizo-
taxia as a syndrome.In order to accomplish this task,it
will be useful to change our conceptualization of schiz-
ophrenia somewhat from the historical view of a dis-
crete, categorical entity whose diagnosis depends on
the clinical symptoms of psychosis. Instead, a more
fruitful approach may be to incorporate a dimensional,
neurodevelopmental perspective in schizophrenia that
includes neurobiological and neuropsychological
measures occurring prior to the development of psy-
chosis (schizotaxia).At some point, molecular biolog-
ical data will also be included in this conception,as the
genes that cause schizotaxia are located.As the valid-
ity of schizotaxia becomes established, the risk (for
subsequent psychosis) provided by its component fea-
tures will become measurable. That knowledge base
will provide the foundation for strategies aimed at the
prevention of schizophrenia, perhaps in the not-too-
distant future. ❏
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ies Programs. 
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Conceptualizaciones respecto 
al riesgo de padecer esquizofrenia: 
sus implicancias clínicas
Históricamente,los criterios diagnósticos del Diagnos-
tic and Statistical Manual of Mental Disorders (DSM)
para esquizofrenia han enfatizado algunas caracterís-
ticas que incluyen: síntomas de psicosis, una diso-
ciación de síntomas de su etiología, una dependencia
de los síntomas clínicos y una aproximación categori-
al para clasificar el trastorno.Aunque este enfoque
resulta bastante útil,también tiene sus limitaciones.En
este artículo se revisan estas limitaciones y se señala la
importancia de incorporar datos recientes,provenientes
de investigaciones acerca de los aspectos genético-
biológicos y del neurodesarrollo de la esquizofrenia,en
las concepciones actuales de este trastorno.También se
revisa el concepto de “esquizotaxia”, que engloba este
punto de vista;aparece antes del comienzo de la psico-
sis e hipotéticamente representaría la vulnerabilidad a
la esquizofrenia. Si esta hipótesis en este punto es cor-
recta, significa que la identificación de individuos con
esquizotaxia eventualmente facilitaría el desarrollo de
estrategias de prevención al reconocer una condición
premórbida (pero clínicamente significativa) para la
esquizofrenia. Sin embargo, la identificación de com-
ponentes biológicos o neuropsicológicos de la esquizo-
taxia facilitaría bases más específicas para el desarrol-
lo de nuevas intervenciones terapéuticas. Nuestros
intentos iniciales para desarrollar protocolos para la
evaluación y tratamiento de la esquizotaxia son alen-
tadores y se revisan en este artículo.
Conceptualisation d’une prédisposition
à la schizophrénie : implications
cliniques
Traditionnellement, les critères diagnostiques du 
Diagnostic and Statistical Manual of Mental Disor-
ders (DSM) pour la schizophrénie ont mis l'accent sur
différents aspects, notamment les symptômes psycho-
tiques;l'indépendance entre symptômes et étiologie;la
place prépondérante de la clinique et une approche
catégorielle pour classer ce trouble. Cependant, bien
que les caractéristiques ainsi définies aient leur utilité,
elles ont aussi des limites. Le présent article passe 
ces dernières en revue,et souligne l’importance d’inté-
grer dans les conceptions actuelles de la schizophrénie
les données récentes sur les origines génétiques/biolo-
giques et neurodéveloppementales de cette maladie.
Cet article fait également le point sur le concept de
“schizotaxie”,qui survient avant l’apparition de la psy-
chose, et constituerait une prédisposition à la schizo-
phrénie.Si notre hypothèse concernant ce point s’avère
exacte, l’identification des personnes schizotaxiques
pourrait faciliter le développement de stratégies pré-
ventives en déterminant un état prémorbide (mais cli-
niquement significatif) de la schizophrénie. De plus,
l’identification des composantes biologiques et neuro-
psychologiques de la schizotaxie devrait fournir des
bases plus spécifiques pour le développement de nou-
veaux traitements.Nos premières tentatives de mise en
place de protocoles pour l’évaluation et le traitement
de la schizotaxie, décrites ici, paraissent d'ores et déjà
encourageantes.163
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